Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CING NASDAQ:LIMN NASDAQ:OKYO NASDAQ:PLRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCINGCingulate$3.99+1.3%$4.52$3.02▼$9.69$21.33M-0.74168,017 shs79,602 shsLIMNLiminatus Pharma$2.71-1.8%$6.36$2.53▼$33.66$71.80MN/A2.31 million shs970,953 shsOKYOOKYO Pharma$2.35+3.1%$2.70$0.90▼$3.35$85.57M-0.09189,287 shs152,538 shsPLRXPliant Therapeutics$1.64+1.2%$1.47$1.10▼$16.10$99.45M1.421.03 million shs517,819 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCINGCingulate+1.27%-4.77%-23.12%+1.01%-50.13%LIMNLiminatus Pharma-1.81%-20.53%-60.03%+270,999,900.00%+270,999,900.00%OKYOOKYO Pharma+3.07%-0.84%-6.37%+27.28%+115.60%PLRXPliant Therapeutics+1.23%+13.10%+7.89%+18.84%-87.27%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCINGCingulate2.3588 of 5 stars3.53.00.00.02.20.80.6LIMNLiminatus PharmaN/AN/AN/AN/AN/AN/AN/AN/AOKYOOKYO Pharma3.0935 of 5 stars3.55.00.00.03.31.70.0PLRXPliant Therapeutics3.9742 of 5 stars3.02.00.04.73.21.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCINGCingulate 3.00Buy$26.25557.89% UpsideLIMNLiminatus Pharma 0.00N/AN/AN/AOKYOOKYO Pharma 3.00Buy$7.00197.87% UpsidePLRXPliant Therapeutics 2.08Hold$8.19399.24% UpsideCurrent Analyst Ratings BreakdownLatest CING, OKYO, PLRX, and LIMN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/22/2025CINGCingulateAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$61.00 ➝ $62.008/10/2025PLRXPliant TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral8/8/2025CINGCingulateRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy8/8/2025PLRXPliant TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$17.00 ➝ $4.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCINGCingulateN/AN/AN/AN/A$1.02 per shareN/ALIMNLiminatus PharmaN/AN/AN/AN/AN/AN/AOKYOOKYO PharmaN/AN/AN/AN/A($0.16) per shareN/APLRXPliant Therapeutics$1.58M63.72N/AN/A$3.59 per share0.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCINGCingulate-$15.55M-$4.10N/AN/AN/AN/A-232.16%-132.07%11/6/2025 (Estimated)LIMNLiminatus PharmaN/AN/A0.00∞N/AN/AN/AN/AN/AOKYOOKYO Pharma-$4.71MN/A0.00N/AN/AN/AN/AN/AN/APLRXPliant Therapeutics-$210.30M-$3.40N/AN/AN/AN/A-73.45%-55.66%11/6/2025 (Estimated)Latest CING, OKYO, PLRX, and LIMN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/19/2025Q2 2025CINGCingulate-$0.82-$1.09-$0.27-$1.09N/AN/A8/7/2025Q2 2025PLRXPliant Therapeutics-$0.62-$0.71-$0.09-$0.71N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCINGCingulateN/AN/AN/AN/AN/ALIMNLiminatus PharmaN/AN/AN/AN/AN/AOKYOOKYO PharmaN/AN/AN/AN/AN/APLRXPliant TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCINGCingulateN/A1.521.52LIMNLiminatus PharmaN/AN/AN/AOKYOOKYO PharmaN/A0.400.40PLRXPliant Therapeutics0.1412.9912.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCINGCingulate41.31%LIMNLiminatus PharmaN/AOKYOOKYO Pharma2.97%PLRXPliant Therapeutics97.30%Insider OwnershipCompanyInsider OwnershipCINGCingulate4.04%LIMNLiminatus PharmaN/AOKYOOKYO Pharma40.46%PLRXPliant Therapeutics8.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCINGCingulate205.41 million5.19 millionNot OptionableLIMNLiminatus PharmaN/A26.02 millionN/AN/AOKYOOKYO Pharma737.61 million22.39 millionNot OptionablePLRXPliant Therapeutics9061.39 million56.48 millionOptionableCING, OKYO, PLRX, and LIMN HeadlinesRecent News About These CompaniesCW Advisors LLC Takes Position in Pliant Therapeutics, Inc. $PLRXAugust 29 at 4:23 AM | marketbeat.comNeedham Sticks to Its Hold Rating for Pliant Therapeutics (PLRX)August 21, 2025 | theglobeandmail.comCiti Reaffirms Their Hold Rating on Pliant Therapeutics (PLRX)August 21, 2025 | theglobeandmail.comPliant Therapeutics price target raised to $1.70 from $1.50 at CitiAugust 11, 2025 | msn.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Recommendation of "Hold" from BrokeragesAugust 9, 2025 | marketbeat.comPliant Therapeutics (NASDAQ:PLRX) Price Target Lowered to $4.00 at Piper SandlerAugust 9, 2025 | marketbeat.comPliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial ResultsAugust 7, 2025 | globenewswire.comXTX Topco Ltd Makes New $630,000 Investment in Pliant Therapeutics, Inc. (NASDAQ:PLRX)August 6, 2025 | marketbeat.comPliant Therapeutics (PLRX) Expected to Announce Earnings on WednesdayJuly 30, 2025 | marketbeat.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Sangamo Biosciences (SGMO), Pliant Therapeutics (PLRX) and Stevanato Group (STVN)July 24, 2025 | theglobeandmail.comPliant Therapeutics Provides Update on BEACON-IPFJune 27, 2025 | globenewswire.comAlnylam, Pliant among stocks yet to face Q2 catalysts: Wells FargoJune 7, 2025 | msn.comPliant Therapeutics presents new fibrosis treatment dataMay 23, 2025 | investing.comPliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International ConferenceMay 21, 2025 | finance.yahoo.comPliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International ConferenceMay 21, 2025 | globenewswire.comPliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comPliant Therapeutics announces workforce reductionMay 3, 2025 | uk.investing.comPliant Therapeutics Announces Workforce Reduction and Cost Saving Initiatives to Support Late-Stage Clinical TrialsMay 3, 2025 | nasdaq.comBay Area biotech company Pliant Therapeutics slashes staff after losing $655 million in valueMay 2, 2025 | msn.comPliant Axes 45% of Workforce To Save Cash, Support Late-Stage Clinical TrialsMay 2, 2025 | biospace.comBPliant Therapeutics cuts workforce by 45% after bexotegrast trial safety woesMay 2, 2025 | fiercebiotech.comFNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesGrab Holdings: Get a Grip Now—Explosive Upside Brewing By Thomas Hughes | August 18, 2025Deeply Undervalued, Micron Technologies Stock Isn’t Pricing in AIBy Thomas Hughes | August 14, 2025Oklo’s Stock Is Set up for a Correction—Buy It When It BouncesBy Thomas Hughes | August 12, 2025Is Viking’s Growth Still Worth the Premium?By Chris Markoch | August 20, 2025Rigetti Stock: A Long-Term Quantum Play Facing Short-Term TestsBy Chris Markoch | August 13, 2025CING, OKYO, PLRX, and LIMN Company DescriptionsCingulate NASDAQ:CING$3.99 +0.05 (+1.27%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$3.97 -0.02 (-0.50%) As of 08/29/2025 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Liminatus Pharma NASDAQ:LIMN$2.71 -0.05 (-1.81%) As of 08/29/2025 04:00 PM EasternLiminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.OKYO Pharma NASDAQ:OKYO$2.35 +0.07 (+3.07%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.28 -0.08 (-3.19%) As of 08/29/2025 05:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.Pliant Therapeutics NASDAQ:PLRX$1.64 +0.02 (+1.23%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.64 0.00 (-0.30%) As of 08/29/2025 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
